Therefore, leptin resistance or Lepr gene polymorphism should be considered in future randomized control trials of long-term metformin treatment on NAFLD in patients preconditioned with T2D. The gene discussed is LEPR; the disease is metabolic dysfunction-associated steatotic liver disease.